Catalysts · BMY · CIK 14272 · page 2 of 3

BMY catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on BMY PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
Mar to Jun 2028Quarter disclosediza-bren (BMS-986507)BMYTopline readoutBreast NeoplasmsScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedpumitamig (BNT327)BMYTopline readoutEarly-Stage Non-Small Cell Lung CancerScheduledClinicalTrials.gov
March 2028Month disclosediza-bren (BMS-986507)BMYPrimary completionBreast NeoplasmsScheduledClinicalTrials.gov
March 2028Month disclosedpumitamig (BNT327)BMYPrimary completionEarly-Stage Non-Small Cell Lung CancerScheduledClinicalTrials.gov
March 2028Month disclosedluspatercept (ACE-536)BMYPrimary completionMyelodysplastic SyndromesScheduledClinicalTrials.gov
Apr to Jul 2028Quarter disclosedgolcadomide (BMS-986369)BMYTopline readoutFollicular LymphomaScheduledClinicalTrials.gov
April 2028Month disclosedgolcadomide (BMS-986369)BMYPrimary completionFollicular LymphomaScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedluspatercept (ACE-536)BMYTopline readout—ScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedzola-cel (CC-97540)BMYTopline readoutLupus Erythematosus, Systemic; Lupus NephritisScheduledClinicalTrials.gov
May 2028Month disclosedluspatercept (ACE-536)BMYPrimary completion—ScheduledClinicalTrials.gov
May 2028Month disclosedzola-cel (CC-97540)BMYPrimary completionLupus Erythematosus, Systemic; Lupus NephritisScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutBipolar Disorder Type I With ManiaScheduledClinicalTrials.gov
June 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionBipolar Disorder Type I With ManiaScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedoral azacitidine (BMS-986345)BMYTopline readoutMyelodysplastic SyndromesScheduledClinicalTrials.gov
July 2028Month disclosedoral azacitidine (BMS-986345)BMYPrimary completionMyelodysplastic SyndromesScheduledClinicalTrials.gov
Aug to Nov 2028Quarter disclosednavlimetostat (BMS-986504)BMYTopline readoutSolid TumorsScheduledClinicalTrials.gov
August 2028Month disclosednavlimetostat (BMS-986504)BMYPrimary completionSolid TumorsScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutSchizophreniaScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedkarxt (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedpumitamig (BNT327)BMYTopline readout—ScheduledClinicalTrials.gov
September 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedpumitamig (BNT327)BMYPrimary completion—ScheduledClinicalTrials.gov
September 2028Month disclosedkarxt (BMS-986510)BMYPrimary completionSchizophreniaScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosedKrazati (adagrasib)BMYTopline readoutAdvanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung CancerScheduledClinicalTrials.gov
October 2028Month disclosedKrazati (adagrasib)BMYPrimary completionAdvanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung CancerScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedxanomeline/trospium chloride (BMS-986510)BMYTopline readoutAlzheimer DiseaseScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedxanomeline/trospium chloride (BMS-986510)BMYTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedBMS-986353BMYTopline readoutSystemic SclerosisScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedevifacotrep (BMS-986511)BMYTopline readoutMajor Depressive DisorderScheduledClinicalTrials.gov
November 2028Month disclosedxanomeline/trospium chloride (BMS-986510)BMYPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
November 2028Month disclosedevifacotrep (BMS-986511)BMYPrimary completionMajor Depressive DisorderScheduledClinicalTrials.gov
November 2028Month disclosedBMS-986353BMYPrimary completionSystemic SclerosisScheduledClinicalTrials.gov
November 2028Month disclosedxanomeline/trospium chloride (BMS-986510)BMYPrimary completionAlzheimer DiseaseScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosednavlimetostat (BMS-986504)BMYTopline readoutCarcinoma, Non-Small-Cell LungScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosediza-bren (BMS-986507)BMYTopline readoutNon-Small Cell Lung CancerScheduledClinicalTrials.gov
December 2028Month disclosediza-bren (BMS-986507)BMYPrimary completionNon-Small Cell Lung CancerScheduledClinicalTrials.gov
December 2028Month disclosednavlimetostat (BMS-986504)BMYPrimary completionCarcinoma, Non-Small-Cell LungScheduledClinicalTrials.gov
January 2029Month disclosedSotyktu (deucravacitinib)BMYPrimary completionPlaque PsoriasisScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedSotyktu (deucravacitinib)BMYTopline readoutPlaque PsoriasisScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosediza-bren (BMS-986507)BMYTopline readoutUrothelial CancerScheduledClinicalTrials.gov
January 2029Month disclosediza-bren (BMS-986507)BMYPrimary completionUrothelial CancerScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedZenbexus (iberdomide hydrochloride)BMYTopline readoutMultiple MyelomaScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedxanomeline/trospium chloride (BMS-986510)BMYTopline readoutSchizophreniaScheduledClinicalTrials.gov
March 2029Month disclosedxanomeline/trospium chloride (BMS-986510)BMYPrimary completionSchizophreniaScheduledClinicalTrials.gov
March 2029Month disclosedZenbexus (iberdomide hydrochloride)BMYPrimary completionMultiple MyelomaScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosednavlimetostat (BMS-986504)BMYTopline readoutPancreatic Ductal AdenocarcinomaScheduledClinicalTrials.gov
May 2029Month disclosednavlimetostat (BMS-986504)BMYPrimary completionPancreatic Ductal AdenocarcinomaScheduledClinicalTrials.gov
Jun to Sep 2029Quarter disclosedkarxt (BMS-986510)BMYTopline readoutAlzheimer Disease; AgitationScheduledClinicalTrials.gov
June 2029Month disclosedkarxt (BMS-986510)BMYPrimary completionAlzheimer Disease; AgitationScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedOpdivo® (nivolumab)BMYTopline readoutCancerScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedkarxt (BMS-986510)BMYTopline readoutIrritability Associated With Autism Spectrum DisorderScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedkarxt (BMS-986510)BMYTopline readoutIrritability Associated With Autism Spectrum DisorderScheduledClinicalTrials.gov
August 2029Month disclosedkarxt (BMS-986510)BMYPrimary completionIrritability Associated With Autism Spectrum DisorderScheduledClinicalTrials.gov
August 2029Month disclosedkarxt (BMS-986510)BMYPrimary completionIrritability Associated With Autism Spectrum DisorderScheduledClinicalTrials.gov
August 2029Month disclosedOpdivo® (nivolumab)BMYPrimary completionCancerScheduledClinicalTrials.gov
Sep to Dec 2029Quarter disclosedKrazati (adagrasib)BMYTopline readoutCarcinoma, Non-Small-Cell LungScheduledClinicalTrials.gov
September 2029Month disclosedKrazati (adagrasib)BMYPrimary completionCarcinoma, Non-Small-Cell LungScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosedSotyktu (deucravacitinib)BMYTopline readoutPlaque PsoriasisScheduledClinicalTrials.gov
October 2029Month disclosedSotyktu (deucravacitinib)BMYPrimary completionPlaque PsoriasisScheduledClinicalTrials.gov
Nov 2029 to Feb 2030Quarter disclosedadmilparant (BMS-986278)BMYTopline readoutPulmonary FibrosisScheduledClinicalTrials.gov
November 2029Month disclosedadmilparant (BMS-986278)BMYPrimary completionPulmonary FibrosisScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedkarxt (BMS-986510)BMYTopline readoutSchizophreniaScheduledClinicalTrials.gov
December 2029Month disclosedkarxt (BMS-986510)BMYPrimary completionSchizophreniaScheduledClinicalTrials.gov
Feb to May 2030Quarter disclosedpumitamig (BNT327)BMYTopline readoutUntreated, Unresectable, or Metastatic Colorectal CancerScheduledClinicalTrials.gov
February 2030Month disclosedpumitamig (BNT327)BMYPrimary completionUntreated, Unresectable, or Metastatic Colorectal CancerScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedSotyktu (deucravacitinib)BMYTopline readoutJuvenile Psoriatic ArthritisScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedkarxt (BMS-986510)BMYTopline readoutSchizophrenia; Autism-Related IrritabilityScheduledClinicalTrials.gov
March 2030Month disclosedSotyktu (deucravacitinib)BMYPrimary completionJuvenile Psoriatic ArthritisScheduledClinicalTrials.gov
March 2030Month disclosedkarxt (BMS-986510)BMYPrimary completionSchizophrenia; Autism-Related IrritabilityScheduledClinicalTrials.gov
May to Aug 2030Quarter disclosedzolacabtagene autoleucel (BMS-986353)BMYTopline readoutChronic Immune Thrombocytopenia; Autoimmune Hemolytic AnemiaScheduledClinicalTrials.gov
May 2030Month disclosedzolacabtagene autoleucel (BMS-986353)BMYPrimary completionChronic Immune Thrombocytopenia; Autoimmune Hemolytic AnemiaScheduledClinicalTrials.gov
Jul to Oct 2030Quarter disclosedOpdivo® (nivolumab)BMYTopline readoutNon-small Cell Lung CancerScheduledClinicalTrials.gov
July 2030Month disclosedOpdivo® (nivolumab)BMYPrimary completionNon-small Cell Lung CancerScheduledClinicalTrials.gov
Sep to Dec 2030Quarter disclosedpumitamig (BNT327)BMYTopline readoutNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
September 2030Month disclosedpumitamig (BNT327)BMYPrimary completionNon-small Cell Lung Cancer (NSCLC)ScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedSotyktu (deucravacitinib)BMYTopline readoutSystemic Lupus Erythematosus; Sjögren's Disease; PsoriasisScheduledClinicalTrials.gov
October 2030Month disclosedSotyktu (deucravacitinib)BMYPrimary completionSystemic Lupus Erythematosus; Sjögren's Disease; PsoriasisScheduledClinicalTrials.gov
Nov 2030 to Feb 2031Quarter disclosedOpdivo® (nivolumab)BMYTopline readout—ScheduledClinicalTrials.gov
November 2030Month disclosedOpdivo® (nivolumab)BMYPrimary completion—ScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
March 6, 2026Sotyktu (deucravacitinib)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 6, 2026—BMYPDUFA date—ScheduledSEC 8-K Exhibit 99.1
February 23, 2026Empliciti (elotuzumab)BMYPrimary completionMultiple MyelomaCompletedClinicalTrials.gov
February 16, 2026Opdivo® (nivolumab)BMYPrimary completionUrinary Bladder Neoplasms; Muscle-Invasive Bladder CancerCompletedClinicalTrials.gov
February 5, 2026—BMYEarnings—CompletedSEC 8-K Exhibit 99.1
January 16, 2026MRTX849BMYPrimary completionAdvanced Colorectal Cancer; Metastatic Colorectal CancerCompletedClinicalTrials.gov
January 16, 2026Camzyos® (mavacamten)BMYPrimary completion—CompletedClinicalTrials.gov
January 15, 2026BB2121BMYPrimary completionMultiple MyelomaCompletedClinicalTrials.gov
December 5, 2025—BMYPDUFA date—ScheduledSEC 8-K Exhibit 99.1
November 25, 2025Camzyos® (mavacamten)BMYPrimary completionCardiomyopathy, HypertrophicCompletedClinicalTrials.gov
November 24, 2025Opdivo Qvantig (hyaluronidase-nvhy; nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
November 12, 2025Opdivo® (nivolumab)BMYPrimary completionMesothelioma, MalignantCompletedClinicalTrials.gov
October 31, 2025ONUREG (azacitidine)BMYPrimary completionLeukemia, Myeloid, AcuteCompletedClinicalTrials.gov
October 30, 2025—BMYEarnings—CompletedSEC 8-K Exhibit 99.1
October 27, 2025Opdivo Qvantig (hyaluronidase-nvhy; nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 1, 2025luspatercept (ACE-536)BMYPrimary completionMyelodysplastic SyndromesCompletedClinicalTrials.gov
September 30, 2025Zeposia (ozanimod hydrochloride)BMYPrimary completionColitis, UlcerativeCompletedClinicalTrials.gov
August 14, 2025cendakimab (CC-93538)BMYPrimary completionEosinophilic EsophagitisCompletedClinicalTrials.gov
August 11, 2025ABECMA (idecabtagene vicleucel)BMYPrimary completionMultiple MyelomaCompletedClinicalTrials.gov
Every catalyst is quoted from BMY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.